Cassava Sciences upgraded by H.C. Wainwright with a new price target
$SAVA
Biotechnology: Pharmaceutical Preparations
Health Care
H.C. Wainwright upgraded Cassava Sciences from Neutral to Buy and set a new price target of $116.00
Save time and jump to the most important pieces.
| Date | Price Target | Rating | Analyst |
|---|---|---|---|
| 10/8/2024 | $116.00 | Neutral → Buy | H.C. Wainwright |
| 7/1/2024 | Buy → Neutral | H.C. Wainwright | |
| 11/16/2022 | $44.00 | Buy → Neutral | B. Riley Securities |
| 1/24/2022 | $108.00 → $72.00 | Buy | B. Riley Securities |
| 7/20/2021 | $97.00 → $124.00 | Buy | HC Wainwright & Co. |
| 7/15/2021 | $100.00 | Overweight → Neutral | Cantor Fitzgerald |
| 7/7/2021 | $80.00 → $190.00 | Buy | Maxim Group |
| 6/23/2021 | $78.00 → $111.00 | Buy | B. Riley Securities |
AUSTIN, Texas, Oct. 31, 2024 (GLOBE NEWSWIRE) -- Cassava Sciences, Inc. (NASDAQ:SAVA), a clinical-stage biotechnology company focused on Alzheimer's disease, announced today that it will hold a conference call on Thursday, November 7th at 8:30 a.m. Eastern Time. Event details: Date:Thursday, November 7thTime:8:30 a.m. Eastern TimeAudio Webcast:https://www.CassavaSciences.com/company-presentationsOrAudio Webcast:https://edge.media-server.com/mmc/p/tzb9j3sy A replay of the audio webcast will also be available on the "Company Presentations" page of the Cassava Sciences website for 90 days following the webcast. About Cassava Sciences, Inc.Cassava Sciences is a clinical-stage biotechnolo
AUSTIN, Texas, Aug. 01, 2024 (GLOBE NEWSWIRE) -- Cassava Sciences, Inc. (NASDAQ:SAVA), a clinical-stage biotechnology company focused on Alzheimer's disease, announced today that it will hold a conference call on Thursday, August 8th at 8:30 a.m. Eastern Time. Event details follow:Date:Thursday, August 8thTime: 8:30 a.m. Eastern TimeAudio Webcast:https://www.CassavaSciences.com/company-presentationsOr Audio Webcast:https://edge.media-server.com/mmc/p/zjvmjjcr A replay of the audio webcast will also be available on the Company Presentations page of the Cassava Sciences' website for 90 days following the webcast. About Cassava Sciences, Inc.Cassava Sciences is a clinical-stage biotechnolo
$126.3 Million In Total Gross Proceeds from Warrant Distribution.Over 1,900 Patients with Alzheimer's Disease Are Randomized in Phase 3 Trials of Simufilam.Over 735 Patients Have Completed a Phase 3 Trial of Simufilam. AUSTIN, Texas, May 10, 2024 (GLOBE NEWSWIRE) -- Cassava Sciences, Inc. (NASDAQ:SAVA), a biotechnology company focused on Alzheimer's disease, today reported financial results for first quarter ended March 31, 2024. Net income was $25.0 million compared to a net loss of $24.3 million for the same period in 2023. Net cash used in operations was $19.1 million during the first quarter of 2024. Cash use for operations for the first half of 2024 is still expected to be $35 to $
10-Q - CASSAVA SCIENCES INC (0001069530) (Filer)
8-K - CASSAVA SCIENCES INC (0001069530) (Filer)
8-K - CASSAVA SCIENCES INC (0001069530) (Filer)
4 - CASSAVA SCIENCES INC (0001069530) (Issuer)
3 - CASSAVA SCIENCES INC (0001069530) (Issuer)
4 - CASSAVA SCIENCES INC (0001069530) (Issuer)
Ms. Nassif brings an extensive track record of successfully developing commercial strategies for multiple FDA-approved drugs Appointment initiates Cassava's commercial readiness strategy as the Company prepares for first Phase 3 topline data readout before year end 2024 AUSTIN, Texas, Nov. 18, 2024 (GLOBE NEWSWIRE) -- Cassava Sciences, Inc. (NASDAQ:SAVA), a clinical-stage biotechnology company focused on developing a novel treatment for Alzheimer's disease, today announced the appointment of Freda Nassif as Chief Commercial Officer, effective today. As a member of the Company's executive leadership team, Ms. Nassif will report to Richard "Rick" Barry, President and Chief Executive of Cas
Top-line Data for RETHINK-ALZ 52-week Phase 3 trial Expected Before the End of 2024 $149.0 Million in Cash and Cash Equivalents at September 30, 2024. Expected To Support Operations Into 2026 Conference Webcast Scheduled for Today at 8:30AM ET AUSTIN, Texas, Nov. 07, 2024 (GLOBE NEWSWIRE) -- Cassava Sciences, Inc. (NASDAQ:SAVA), a clinical-stage biotechnology company focused on developing a novel treatment for Alzheimer's disease, today reported financial results for the third quarter ended September 30, 2024. "We look forward to the release of top-line results from RETHINK-ALZ, our first Phase 3 trial for simulfilam, by the end of 2024," said Rick Barry, President and Chief Executive
AUSTIN, Texas, Oct. 31, 2024 (GLOBE NEWSWIRE) -- Cassava Sciences, Inc. (NASDAQ:SAVA), a clinical-stage biotechnology company focused on Alzheimer's disease, announced today that it will hold a conference call on Thursday, November 7th at 8:30 a.m. Eastern Time. Event details: Date:Thursday, November 7thTime:8:30 a.m. Eastern TimeAudio Webcast:https://www.CassavaSciences.com/company-presentationsOrAudio Webcast:https://edge.media-server.com/mmc/p/tzb9j3sy A replay of the audio webcast will also be available on the "Company Presentations" page of the Cassava Sciences website for 90 days following the webcast. About Cassava Sciences, Inc.Cassava Sciences is a clinical-stage biotechnolo
Ms. Nassif brings an extensive track record of successfully developing commercial strategies for multiple FDA-approved drugs Appointment initiates Cassava's commercial readiness strategy as the Company prepares for first Phase 3 topline data readout before year end 2024 AUSTIN, Texas, Nov. 18, 2024 (GLOBE NEWSWIRE) -- Cassava Sciences, Inc. (NASDAQ:SAVA), a clinical-stage biotechnology company focused on developing a novel treatment for Alzheimer's disease, today announced the appointment of Freda Nassif as Chief Commercial Officer, effective today. As a member of the Company's executive leadership team, Ms. Nassif will report to Richard "Rick" Barry, President and Chief Executive of Cas
AUSTIN, Texas, Sept. 26, 2024 (GLOBE NEWSWIRE) -- Cassava Sciences, Inc. ("Cassava" or the "Company") (NASDAQ:SAVA), a biotechnology company focused on Alzheimer's disease, today announced that it has reached a settlement with the U.S. Securities and Exchange Commission ("SEC") of negligence-based disclosure charges that resolve a previously-disclosed SEC investigation into statements made by the Company pertaining to the results of its 2020 Phase 2b clinical trial of simufilam and related matters. Two former senior employees of the Company also settled negligence-based disclosure charges brought by the SEC. Cassava, without admitting or denying the SEC's allegations, agreed to pay a mone
AUSTIN, Texas, Sept. 09, 2024 (GLOBE NEWSWIRE) -- Cassava Sciences, Inc. (NASDAQ:SAVA), a biotechnology company focused on Alzheimer's disease, today announced it has concluded its search for a Chief Executive Officer and that its Board of Directors has named Richard (Rick) Barry as CEO. Mr. Barry has served as a director of Cassava since June 2021. On July 17 of this year, the Board appointed him Executive Chairman of the Board and the Company's principal executive officer and while undertaking a now completed search for a permanent CEO. In keeping with the company's pledge to follow good governance principles, the Company is separating the positions of CEO and Chairman by appointing Cla
H.C. Wainwright upgraded Cassava Sciences from Neutral to Buy and set a new price target of $116.00
H.C. Wainwright downgraded Cassava Sciences from Buy to Neutral
B. Riley Securities downgraded Cassava Sciences from Buy to Neutral and set a new price target of $44.00
Cassava Sciences (NASDAQ:SAVA) has outperformed the market over the past 5 years by 43.6% on an annualized basis producing an average annual return of 56.63%. Currently, Cassava Sciences has a market capitalization of $597.06 million. Buying $1000 In SAVA: If an investor had bought $1000 of SAVA stock 5 years ago, it would be worth $9,083.94 today based on a price of $12.45 for SAVA at the time of writing. Cassava Sciences's Performance Over Last 5 Years Finally -- what's the point of all this? The key insight to take from this article is to note how much of a difference compounded returns can make in your cash growth over a period of time. This article was generated by Benzinga's automat
On Monday, Rick Barry, the executive chairman of Cassava Sciences Inc (NASDAQ:SAVA), wrote a letter to shareholders and employees. He said the company is in the final stages of testing its Alzheimer’s drug candidate, simufilam, with significant financial and emotional stakes. The company is conducting Phase 3 trials to demonstrate the drug’s efficacy and safety. Related: Alzheimer’s-Focused Cassava Sciences Faces Controversy as Key Collaborator Accused of Scientific Misconduct. These trials, costing hundreds of millions of dollars, are essential for determining if simufilam can significantly impact the lives of Alzheimer’s patients and their families. Cassava Sciences’ executi
Shares of CrowdStrike Holdings, Inc. (NASDAQ:CRWD) fell sharply during Monday’s session. Guggenheim analyst John Difucci downgraded the stock from Buy to Neutral, while BTIG analyst Gray Powell downgraded the stock from Buy to Neutral. CrowdStrike shares dipped over 11% on Friday after the company suffered a major outage impacting businesses around the world. Selective Insurance Group shares dipped 13.2% to $264.65 on Friday. Here are some other stocks moving in today’s mid-day session. Gainers MIRA Pharmaceuticals, Inc. (NASDAQ:MIRA) shares climbed 148% to $1.98 after the company announced new preclinical study results for its novel oral ketamine analog, Ketamir-2. CareMa
SC 13G/A - CASSAVA SCIENCES INC (0001069530) (Subject)
SC 13G/A - CASSAVA SCIENCES INC (0001069530) (Subject)
SC 13G/A - CASSAVA SCIENCES INC (0001069530) (Subject)